01615nas a2200337   4500000000100000008004100001260001300042653002600055653002400081653002600105653001200131653003800143653001600181653001100197653002100208653001200229653001700241653002500258653003200283653001700315100001800332700001800350700001300368700001700381245007300398856004100471300001000512490000700522520073400529022001401263       1992                            d  c1992 Dec10aAntibodies, Bacterial10aAntigens, Bacterial10aArthritis, Rheumatoid10aBuffers10aEnzyme-Linked Immunosorbent Assay10aGlycolipids10aHumans10aImmunoglobulin G10aleprosy10aLyme Disease10aMycobacterium leprae10aSensitivity and Specificity10aTromethamine1 aSticht-Groh V1 aAlvarenga A E1 aVettom L1 aBallestrem W00aUse of a different buffer system in the phenolic glycolipid-I ELISA.  uhttp://ila.ilsl.br/pdfs/v60n4a07.pdf  a570-40 v603 a<p>By changing the buffer system in the phenolic glycolipid-I (PGL-I) enzyme-linked immunosorbent assay (ELISA) the sensitivity of the test was increased without altering its specificity. Using a Tris-HCl buffer, significant titers of &gt; or = 1:300 were found in 53.1% of the sera in paucibacillary (PB) and 98.0% of the sera in multibacillary (MB) groups of patients. Titer levels were also significantly increased. In the PB group of patients with Tris-HCl, the highest titer detected was 1:1200; in the MB group of patients, 1:76,800. Through this modification of the buffer system a more sensitive test was obtained thereby increasing the detectable level of PGL-I antibodies in both the PB and MB groups of patients.</p>
  a0148-916X